A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design

INTRODUCTION: Limited data from controlled clinical trials are available for men who experience biochemical recurrence after definitive therapy for prostate cancer. In the absence of overt metastases, patients with non-metastatic castration-sensitive prostate cancer (nmCSPC) often receive androgen d...

Descripción completa

Detalles Bibliográficos
Autores principales: Freedland, Stephen J, De Giorgi, Ugo, Gleave, Martin, Rosbrook, Brad, Shen, Qi, Sugg, Jennifer, Haas, Gabriel P, Shore, Neal D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Urology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362713/
https://www.ncbi.nlm.nih.gov/pubmed/34385241
http://dx.doi.org/10.1136/bmjopen-2020-046588

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362713/
https://www.ncbi.nlm.nih.gov/pubmed/34385241
http://dx.doi.org/10.1136/bmjopen-2020-046588

Ejemplares similares